

## Press release

Please fill in this form and return it to [graduateschoolhealth@au.dk](mailto:graduateschoolhealth@au.dk) in Word format no later than three weeks prior to your defence.

### Basic information

Name: Eva Boysen Fynboe Ebert

Email: [evhase@rm.dk](mailto:evhase@rm.dk) Phone: 28896884

Department of: Clinical Medicine

Main supervisor: Peter Meldgaard

Title of dissertation: Use of a qPCR-based blood test for identification of response in patients with EGFR mutated non-small cell lung cancer on systemic treatment

Date for defence: September 11<sup>th</sup> 2020 at (time of day): 2.00 PM Place: Aarhus University Hospital, Room 114-101

Press release (Danish)

**Blodprøveovervågning af systemisk behandlingsrespons hos patienter med udbredt lungekræft**

Opdagelsen af onkogene drivere og muligheden for at målrette behandlingen mod sådanne drivere har været et stort gennembrud inden for kræftbehandling. Med tiden vil tumorkomponenterne ændre sig som et modsvar på den behandling, de udsættes for. Derfor er det nødvendigt nøje at monitorere tumors udvikling over tid for at kunne tilbyde den mest præcise behandling til den enkelte patient. Muligheden for denne overvågning er blevet markant bedre med opdagelsen af cirkulerende tumor-DNA (ctDNA) i blodet. Brug af ctDNA i den kliniske hverdag er dog endnu ikke bredt implementeret. I et stort, dansk studie undersøges muligheden for at benytte ctDNA til at forudsige respons på medicinsk behandling samt overvåge sygdommen hos patienter med udbredt, EGFR-muteret lungekræft.

Resultaterne er sammenfattet i et nyt ph.d.-projekt fra Aarhus Universitet, Health. Projektet er gennemført af Eva Boysen Fynboe Ebert, der forsvarede det d. 9/11 2020.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 11/9 kl. 14 i 114-101 auditorium, Aarhus Universitetshospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus N.

Titlen på projektet er "Use of a qPCR-based blood test for identification of response in patients with EGFR mutated non-small cell lung cancer on systemic treatment". Yderligere oplysninger: Ph.d.-studerende Eva Boysen Fynboe Ebert, e-mail: [evhase@rm.dk](mailto:evhase@rm.dk), tlf. 28896884.

Bedømmelsesudvalg:

Martin Reck, Professor, MD, PhD

Department of Thoracic Oncology

Lung Clinic Grosshansdorf, Germany

Stephen Finn, Associate professor, MD, PhD

Cancer Molecular Diagnostics Laboratory

St. James's Hospital, Ireland

Hans Jürgen Hoffmann, Professor, PhD (Formand)

Department of Respiratory Disease

Aarhus University Hospital, Denmark

Press release (English)

**Blood sample monitoring of systemic treatment response in patients with advanced lung cancer**

The discovery of oncogenic drivers and the ability to target treatment towards such drivers has been a major breakthrough in cancer treatment. Over time, the tumor components will change in response to the treatment to which they are exposed. Therefore, it is necessary to closely monitor tumor development over time in order to offer the most accurate treatment to the individual patient. The possibility of this monitoring has improved markedly with the discovery of circulating tumor DNA (ctDNA) in the blood. However, the use of ctDNA in the everyday clinical practice is not yet widely implemented. In a large Danish study, the possibility of using ctDNA to predict response to medical treatment as well as monitoring the disease in patients with advanced, EGFR-mutated lung cancer, was investigated.

The project was carried out by Eva Boysen Fynboe Ebert, who is defending her dissertation on 11/9 2020.

The defence is public and takes place on 11/9 at 2.00 PM in auditorium 114-101, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus N. The title of the project is "Use of a qPCR-based blood test for identification of response in patients with EGFR mutated non-small cell lung cancer on systemic treatment". For more information, please contact PhD student Eva Boysen Fynboe Ebert, email: evhase@rm.dk, Phone +45 2889 6884.

Assessment committee:

Martin Reck, Professor, MD, PhD  
Department of Thoracic Oncology  
Lung Clinic Grosshansdorf, Germany

Stephen Finn, Associate professor, MD, PhD  
Cancer Molecular Diagnostics Laboratory  
St. James's Hospital, Ireland

Hans Jürgen Hoffmann, Professor, PhD (chairman)  
Department of Respiratory Disease  
Aarhus University Hospital, Denmark

## **Permission**

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.